Abstract:Background: Sleep disorders have been found to be associated with hypertension in both cross- sectional and longitudinal epidemiological studies. Tetrandrine, a major component of Stephania tetrandra, is well known as an antihypertensive agent. The anti- hypertension mechanism mainly relies on its L- type calcium channel blocking property. In the previous study, tetrandrine revealed both anti- hypertension and hypnotic effects in spontaneously hypertensive rats (SHRs).Purpose: This study aims to elucidate whether the antihypertensive mechanism of tetrandrine in SHRs is relevant to its hypnotic effect. Design/Methods: Sleep- wake behavior of the SHRs was detected by electroencephalography (EEG) and electromyography (EMG) recordings. Blood pressure was measured by noninvasive blood pressure tail cufftest. Immunohistochemistry was performed to evaluate the noradrenergic neuronal activity. The level of norepinephrine (NE) was detected by HPLC- ECD.Results: Amlodipine (100 mg/kg, i.g.), the well- known L- type Ca2+ channel blockers (CCBs) exhibited remarkable antihypertensive activities in SHRs, but did not show effects on sleep of SHRs. Tetrandrine (30 and 60 mg/kg/day, i.g.) significantly suppressed blood pressure of SHRs. Meanwhile, tetrandrine (60 mg/kg/day, i.g.) remarkably increased non- rapid eye movement sleep (NREMS) time, bouts and mean duration. The hypnotic effect of tetrandrine was potentiated by prazosin (0.5 mg/kg, i. p.) but attenuated by yohimbine (2 mg/kg, i.p.). Administration of tetrandrine (60 mg/kg/day, i.g.) not only significantly decreased c- Fos positive ratio of noradrenergic neurons in the locus coeruleus (LC), but also significantly decrease NE in the endogenous sleep- wake regulating pathways including LC, hypothalamus and ventrolateral preoptic nucleus (VLPO).Conclusion: In spite of a good potency in blocking L-type Ca2+ channel, the hypnotic effects of tetrandrine may be related to its suppressing effects on the noradrenergic system other than to block calcium channels. As a multi- targets drug, tetrandrine might be favorable to the hypertension patients who suffered poor sleep. (C) 2016 Elsevier GmbH. All rights reserved.

Tetrandrine inhibits aldosterone synthesis by covalently targeting CYP11A1 to attenuate hypertension

Tetrandrine, an Alkaloid from S. Tetrandra Exhibits Anti-Hypertensive and Sleep-Enhancing Effects in SHR Via Different Mechanisms.

Advanced Progress on the Effect and Mechanism of Tetrandrine

Pharmacology of Tetrandrine and Its Therapeutic Use in Digestive Diseases.

Tetrandrine, an Antihypertensive Alkaloid, Improves the Sleep State of Spontaneously Hypertensive Rats (Shrs).

Insights on Exploring the Therapeutic Potential and Structural Modification of Tetrandrine.

Tetrandrine Inhibits the Wnt/β-Catenin Signalling Pathway and Alleviates Osteoarthritis: an in Vitro and in Vivo Study

Tetrandrine mediates renal function and redox homeostasis in a streptozotocin-induced diabetic nephropathy rat model through Nrf2/HO-1 reactivation

Tetrandrine inhibits activation of rat hepatic stellate cells stimulated by transforming growth factor-β in vitro via up-regulation of Smad 7

Progress on structural modification of Tetrandrine with wide range of pharmacological activities

Hypotensive Activity of Tetrandrine in Rats

Tetrandrine Regulates Hepatic Stellate Cell Activation Via TAK1 and NF-κB Signaling.

Pharmacological Actions of Tetrandrine in Inflammatory Pulmonary Diseases.

Hypotensive activity of tetrandrine in rats. Investigation into its mode of action.

Efficacy of tetrandrine on lowering intraocular pressure in animal model with ocular hypertension.

Tetrandrine Blocks Cardiac Hypertrophy by Disrupting Reactive Oxygen Species-Dependent Erk1/2 Signalling

Ursolic Acid Alleviates Tetrandrine-Induced Hepatotoxicity by Competitively Binding to the Substrate-Binding Site of Glutathione S-transferases.

Dissection of the antitumor mechanism of tetrandrine based on metabolite profiling and network pharmacology

Discovery of MT-1207: A Novel, Potent Multitarget Inhibitor as a Promising Clinical Candidate for the Treatment of Hypertension

Tetrandrine alleviates atherosclerosis via inhibition of STING-TBK1 pathway and inflammation in macrophages

Tetrandrine Attenuates Podocyte Injury by Inhibiting TRPC6-Mediated RhoA/ROCK1 Pathway